Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
NCT01618513
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
84
Enrollment
OTHER
Sponsor class
Conditions
Acromegaly
Interventions
DRUG:
Sandostatin® LAR
Sponsor
University of Aarhus
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]